Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Inovio Pharmaceuticals has partnered with VGX International to co-develop Inovio's SynCon therapeutic vaccines for hepatitis B and C infections.
Subscribe to our email newsletter
As per the deal, VGX International will receive marketing rights for the vaccines in Asia, except Japan, and will fund IND-enabling and initial phase I and II clinical studies.
Inovio on the other hand will receive payments based on the achievement of clinical milestones and royalties based on sales in the licensed territories.
Synthetic multi-antigen hepatitis C virus (HCV) vaccine targeting the antigens NS3/4A will be the first product to enter clinical testing, which will be delivered with Inovio’s Cellectra delivery device
The positive preclinical results from Inovio’s novel SynCon vaccine targeting NS3/4A support the development of the vaccines.